KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Non-Current Liabilities (2019 - 2025)

Esperion Therapeutics (ESPR) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $759.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 3.63% year-over-year to $759.1 million, compared with a TTM value of $759.1 million through Dec 2025, up 3.63%, and an annual FY2025 reading of $759.1 million, up 3.63% over the prior year.
  • Total Non-Current Liabilities was $759.1 million for Q4 2025 at Esperion Therapeutics, down from $807.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $807.9 million in Q3 2025 and bottomed at $332.8 million in Q4 2021.
  • Average Total Non-Current Liabilities over 5 years is $506.6 million, with a median of $420.8 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 608.43% in 2021, then tumbled 41.44% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $332.8 million in 2021, then grew by 6.03% to $352.9 million in 2022, then rose by 19.26% to $420.8 million in 2023, then surged by 74.07% to $732.5 million in 2024, then increased by 3.63% to $759.1 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ESPR at $759.1 million in Q4 2025, $807.9 million in Q3 2025, and $773.2 million in Q2 2025.